131 related articles for article (PubMed ID: 36034180)
1. Engineered multivalent self-assembled binder protein against SARS-CoV-2 RBD.
Britton D; Punia K; Mahmoudinobar F; Tada T; Jiang X; Renfrew PD; Bonneau R; Landau NR; Kong XP; Montclare JK
Biochem Eng J; 2022 Nov; 187():108596. PubMed ID: 36034180
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
3. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
mBio; 2021 May; 12(3):. PubMed ID: 33975938
[TBL] [Abstract][Full Text] [Related]
4. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
[TBL] [Abstract][Full Text] [Related]
5. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
6. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
7. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
Lata S; Akif M
J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
[TBL] [Abstract][Full Text] [Related]
8. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
9. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
10. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
11. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
12. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
13. Engineering defensin α-helix to produce high-affinity SARS-CoV-2 spike protein binding ligands.
Fernandes LA; Gomes AA; Guimarães BG; de Lourdes Borba Magalhães M; Ray P; da Silva GF
Protein Sci; 2022 Jun; 31(6):e4355. PubMed ID: 35634778
[TBL] [Abstract][Full Text] [Related]
14. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
[TBL] [Abstract][Full Text] [Related]
16. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Lan J; Ge J; Yu J; Shan S; Zhou H; Fan S; Zhang Q; Shi X; Wang Q; Zhang L; Wang X
Nature; 2020 May; 581(7807):215-220. PubMed ID: 32225176
[TBL] [Abstract][Full Text] [Related]
17. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
18. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.
Zeng X; Li L; Lin J; Li X; Liu B; Kong Y; Zeng S; Du J; Xiao H; Zhang T; Zhang S; Liu J
Antib Ther; 2020 Apr; 3(2):95-100. PubMed ID: 33912790
[TBL] [Abstract][Full Text] [Related]
19. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
Basit A; Ali T; Rehman SU
J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
[TBL] [Abstract][Full Text] [Related]
20. Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization.
Chen J; Miao L; Li JM; Li YY; Zhu QY; Zhou CL; Fang HQ; Chen HP
World J Gastroenterol; 2005 Oct; 11(39):6159-64. PubMed ID: 16273643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
